Actas urologicas espanolas · 2026
New biomarker for erectile dysfunction: Soluble tumor necrosis factor-like weak inducer of apoptosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iplikci A, Efiloglu O, Kado A, Erman H, Yildirim A
Аннотация
INTRODUCTION: The soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) is a cytokine that modulates inflammatory and atherogenic reactions. In our study, we aimed to determine whether sTWEAK could be a biomarker of erectile dysfunction (ED).
METHODS: Ninety patients diagnosed with ED and 90 healthy participants were prospectively enrolled during the period of September 2021-September 2023. Participants were divided into three groups according to International Index of Erectile Function (IIEF) Erectile Function Domain scores; severe disease (1-10), moderate-mild disease (11-21) and healthy control (22-30). All participants filled out Beck Depression Inventory (BDI). Blood samples were collected for complete blood count, biochemical analysis and hormonal assessment.
RESULTS: sTWEAK levels were higher in patients and increased with the severity of the disease as well. Healthy participants had lower BDI score (P = .001) and erythrocyte sedimentation rate (P = .001). Analysis with ROC curve demonstrated good area under curve value for sTWEAK (0.776, P = .001) in predicting ED. Optimal threshold level was determined as 5,41 ng/mL (71.1% sensitivity and 71.1% specificity).
CONCLUSIONS: We revealed that there is a significant association between sTWEAK levels and severity of disease, therefore we belive that sTWEAK pathway has a role in the pathogenesis of atherosclerosis in patients with ED.
METHODS: Ninety patients diagnosed with ED and 90 healthy participants were prospectively enrolled during the period of September 2021-September 2023. Participants were divided into three groups according to International Index of Erectile Function (IIEF) Erectile Function Domain scores; severe disease (1-10), moderate-mild disease (11-21) and healthy control (22-30). All participants filled out Beck Depression Inventory (BDI). Blood samples were collected for complete blood count, biochemical analysis and hormonal assessment.
RESULTS: sTWEAK levels were higher in patients and increased with the severity of the disease as well. Healthy participants had lower BDI score (P = .001) and erythrocyte sedimentation rate (P = .001). Analysis with ROC curve demonstrated good area under curve value for sTWEAK (0.776, P = .001) in predicting ED. Optimal threshold level was determined as 5,41 ng/mL (71.1% sensitivity and 71.1% specificity).
CONCLUSIONS: We revealed that there is a significant association between sTWEAK levels and severity of disease, therefore we belive that sTWEAK pathway has a role in the pathogenesis of atherosclerosis in patients with ED.